Clinical trials are a crucial part of the search for improved diagnoses and treatments for amyloidosis. Clinical trials rely upon the participation of patients and their families. While the patient may or may not benefit from a new or investigational treatment, the information learned from their participation will certainly help others.
Most clinical trials are registered with the National Institute of Health (NIH). Sites where clinical trial information can be found are:
Another site to find trials for AL amyloidosis is www.cancer.gov/clinicaltrials provided by the National Cancer Institute. At this site select multiple myeloma as the type of cancer and primary systemic amyloidosis as the subtype
Announcing New Trials Recruiting Patients
The Effect of Diflunisal on Familial Amyloidosis
Boston University School of Medicine
Memorial Sloan-Kettering Clinical Trials
Phase I/II Study of Human Immune Globulin Intravenous in Patients with Cardiac-Dominant AL Amyloidosis
University of Tennessee – Graduate School of Medicine
Knoxville, TN
Alan Solomon, MD – Principal Investigator.
Eligibility Criteria
Patients must have AL amyloidosis with cardiac involvement
Prior treatment is not a disqualifier for eligibility
Patients must be able to visit the clinic in Knoxville every week for the first 3 months, then every 2 weeks for 9 months
There is no charge for the immune globulin. All other costs for evaluations, lab tests and medications must be covered by the patient/insurer
For more information contact Dr. Alan Solomon at 865-544-9165 or asolomon@mc.utmck.edu
Safety and Efficacy Study of Fx-1006A in Patients with Familial Amyloid Polyneuropathy (FAP)
U.S. enrollment is now open.
FoldRx Pharmaceuticals, Inc.
Linda Robertson, RN – Primary US company contact
Eligibility Criteria
Age: 18 years – 75 years
Gender: both
Amyloid documented by biopsy
Documented V30M TTR mutation
Peripheral and/or autonomic neuropathy
If female, post-menopausal, surgically sterilized or willing to use an acceptable method of birth control
If male with partner of childbearing potential, willing to use an acceptable method of birth control
Exclusion Criteria
Chronic use of non-steroidal anti-inflammatory drugs
Primary amyloidosis
If female, pregnant or breast feeding
Prior liver transplant
Positive results for hepatitis B surface antigen, anti-hepatitis C virus (HCV) or human immunodeficiency virus (HIV)
Renal insufficiency or liver function test abnormalities
Lenalidomide, Cyclophosphamide, and Dexamethasone in Treating Patients with
Primary Systemic Amyloidosis
Purpose: This phase II trial is studying how well giving lenalidomide together with
cyclophosphamide and dexamethasone works in treating patients with primary systemic
amyloidosis.
Contact: Clinical Trials Office – Mayo Clinic 507-538-7623
